Anti-inflammatory therapy by intravenous delivery of non-heparan sulfate-binding CXCL12.

FASEB J · 2009 · PMC2791779 · PMID 19667120

Europe PMC DOI

hedged sentence

0.0800

closest p · 1.6× alpha

0.0800

boldest claim

The sentences

did not reach statistical significanceP =0.08so close (0.05 < p ≤ 0.1)

A small reduction in CXCR4 was also seen at this time after administration of 20 μg wild-type CXCL12, although this did not reach statistical significance ( P =0.08).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.